Cowen and Company’s Axsome Therapeutics AXSM Stock Holding History

Cowen and Company’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,536	Closed	-$365K	–	419
2019 Q4	$365K	Buy	+3,536	New	+$143K	0.03%	147

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cowen and Company's AXSM Position: Q1 2020 in Review

Cowen and Company sold out of Axsome Therapeutics (AXSM) in Q1 2020, closing a stake of 3,536 shares — an estimated $365K sold.

Cowen and Company first reported a position in AXSM in Q4 2019 and held it in 1 quarter. The position peaked at $365K in Q4 2019. 163 funds tracked by Wall St. Rank hold AXSM as of Q1 2020.

Cowen and Company reported no remaining Axsome Therapeutics position as of Q1 2020 after selling out during the quarter.
Cowen and Company sold 3,536 Axsome Therapeutics shares in Q1 2020, an estimated $365K.
Cowen and Company first reported a position in Axsome Therapeutics in Q4 2019 and held it in 1 quarter.
Cowen and Company's Axsome Therapeutics position peaked at $365K in Q4 2019.
163 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2020.

Based on Cowen and Company's 13F filing for Q1 2020, filed 11 May 2020.